Osimertinib or Platinum-Pemetrexed in <i>EGFR</i> T790M-Positive Lung Cancer

  • Mok, T. S.; 
  • Wu, Y. -L.; 
  • Ahn, M. -J.; 
  • Garassino, M. C.; 
  • Kim, H. R.; 
  • 외 12명
Citations

WEB OF SCIENCE

2,490
Citations

SCOPUS

3,310

초록

BACKGROUND Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. METHODS In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2: 1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy. The primary end point was investigator-assessed progression-free survival. RESULTS The median duration of progression-free survival was significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months; hazard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P< 0.001). The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P< 0.001). Among 144 patients with metastases to the central nervous system (CNS), the median duration of progression-free survival was longer among patients receiving osimertinib than among those receiving platinum therapy plus pemetrexed (8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49). The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%). CONCLUSIONS Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy.

키워드

OPEN-LABEL; 1ST-LINE TREATMENT; T790M MUTATION; PATIENTS PTS; PHASE-III; RESISTANCE; CHEMOTHERAPY; GEFITINIB; ERLOTINIB; AZD9291
제목
Osimertinib or Platinum-Pemetrexed in <i>EGFR</i> T790M-Positive Lung Cancer
저자
Mok, T. S.; Wu, Y. -L.; Ahn, M. -J.; Garassino, M. C.; Kim, H. R.; Ramalingam, S. S.; Shepherd, F. A.; He, Y.; Akamatsu, H.; Theelen, W. S. M. E.; Lee, C. K.; Sebastian, M.; Templeton, A.; Mann, H.; Marotti, M.; Ghiorghiu, S.; Papadimitrakopoulou, V. A.
DOI
10.1056/NEJMoa1612674
발행일
2017-02-16
유형
Article
저널명
New England Journal of Medicine
권
376
호
7
페이지
629 ~ 640